Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Results of a U.K. study suggest that an easy-to-distribute COVID-19 vaccine from Novavax is effective against the new variant.

Coronavirus Vaccine From Novavax Is 89.3% Effective

You'd shoot 30%-plus higher too if you tested as well as the company's vaccine candidate.

Why Novavax Was a Coronavirus Stock Winner After Hours Today

Other vaccines have also proven less effective against a new coronavirus strain discovered in South Africa.

Novavax Covid Vaccine Is Highly Effective Against U.K. Variant But Struggled In South Africa, Data Shows

Novavax on Thursday said its experimental coronavirus vaccine was highly effective at preventing the disease in a UK trial, but disappointing results from a study of the same shot in South Africa raises questions. The vaccine developer said that its shot was 89% effective at preventing symptomatic COVID-19, based on a trial of more than 15,000 patients taking place in the UK. The company published the results in a press release, and said it plans to submit them to a scientific journal for review.

Novavax says its coronavirus vaccine was 89% effective in a UK trial, but it didn't work nearly as well in a second study

Novavax said late Thursday its experimental coronavirus vaccine was nearly 90% effective in a Phase 3 test. The news prodded NVAX stock to surge in after-hours trading.

Novavax Stock Surges After Covid Vaccine Proves Nearly 90% Effective

Novavax Inc. shares jumped more than 20% in after-hours trading Thursday, after the company revealed results of studies that showed its proposed COVID-19 vaccine is nearly 90% effective overall, but much less effective against a new variant.

Novavax stock soars more than 20% after COVID-19 vaccine study shows nearly 90% efficacy in UK, less against new South African variant

Biotech firm Novavax said Thursday that its coronavirus vaccine was more than 89% effective in protecting against Covid-19.

Novavax says Covid vaccine is more than 89% effective

First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

This company is nearing the vaccine race finish line.

Why Novavax May Extend Its 2,000% Gain

Novavax's experimental Covid-19 shot is being closely watched, given some promising early-stage data and the company's move to line up significant manufacturing capacity. Here's a quick overview of what has been happening with Novavax stock in recent weeks.

Novavax Stock Update: Planned Capital Raise, New Supply Deals

Novavax has significant upside if its phase 3 data are positive.

Why the No. 1 Healthcare Stock of 2020 Is Still a Buy

It makes sense to hold your NVAX stock shares now as Novavax is working hard to promote the distribution of its Covid-19 vaccine doses. The post Novavax Is a Vaccine Investment That You Shouldn't Ignore appeared first on InvestorPlace.

Novavax Is a Vaccine Investment That You Shouldn't Ignore

Novavax has been consolidating for months now. While doubts linger, NVAX stock could have serious upside if its Covid-19 vaccine works.

Novavax's Recent Consolidation Could Lead to More Gains

Canadian government commits to purchase 52 million doses with option for additional 24 million of Novavax candidate vaccine, NVX-CoV2373 Canadian government commits to purchase 52 million doses with option for additional 24 million of Novavax candidate vaccine, NVX-CoV2373

Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine

GAITHERSBURG, Md., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Madelyn ‘Lyn' Caltabiano, Ph.D. to the position of Senior Vice President, Global Program Management. In this newly created role, Dr. Caltabiano will lead and expand the Global Program Management organization for the company's pipeline and will develop appropriate strategies to assess the company's operational performance, including areas related to portfolio valuation, milestone decision making and prioritization. She will report directly to Stanley C. Erck, President and Chief Executive Officer.

Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management

Intuitive Surgical

Retractable Technologies

Investing in the recovery from the pandemic could pay off big.

These 3 Healthcare Stocks Are the Best Bets for 2021

Beam Global

Blink Charging

Celsius Holdings

Co-Diagnostics

Cardiff Oncology

Genprex

GrowGeneration Corp

Kirkland's

Marathon Digital Holdings

Nautilus

Plug Power

Riot Blockchain

AgEagle Aerial Systems

Veritone

Vaxart

Waitr Holdings Inc

This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued investor interest in 2020.

The 17 Stocks That Outperformed Tesla In 2020

Axsome Therapeutics

Johnson & Johnson

Take a look at a few trending biotech stocks and decide if this is something you want to invest in.

Are Biotech Stocks a Good Idea Right Now?

Last year's stock market star is getting ready for its big moment -- or, has it already happened?

3 Reasons to Buy Novavax Stock, and 1 Reason to Sell

These companies' vaccines could bring in billions of dollars in revenue.

Better Coronavirus Stock: Novavax or Vaxart?

After a monster 2020 rally, NVAX stock has been quiet so far in 2021. But with good news building, this year too should be a strong one.

There's Still Plenty of Good News Surrounding Novavax

A10 Networks

National Vision Hlds

Smith & Wesson Brands

Tronox

Unisys

VirnetX

These are the small cap stocks with the best value, fastest growth, and most momentum for February 2021.

Top Small Cap Stocks for February 2021

The NVAX stock battle now is heating up between the support below and the resistance above ... and the bulls have the momentum.

Novavax Stock Is Once Again Ready to Pop

AstraZeneca

Moderna

Pfizer

Covid-19 pharma stocks like NVAX stock and BNTX stock are making headlines as Joe Biden promises to vaccinate 100 million Americans. The post Covid-19 Vaccine Roundup: 5 Pharma Stocks Making the Biggest Headlines Today appeared first on InvestorPlace.

Covid-19 Vaccine Roundup: 5 Pharma Stocks Making the Biggest Headlines Today

Novavax has achieved considerable clinical success with its Covid-19 vaccine. However, NVAX stock is too expensive.

News for Novavax Stock (NVAX)